RAKUTEN MEDICAL
LIVE

Serial Number

90981512

Owner

RAKUTEN, INC.

Attorney

Anna Kurian Shaw

First Use Date

Jan 10, 2023

Filing Date

Nov 11, 2020

Add to watchlist:

No watchlists yet
View on USPTO

RAKUTEN MEDICAL Trademark

Serial Number: 90981512 • Registration: 8052456

RAKUTEN MEDICAL is a trademark filed by RAKUTEN, INC. on November 11, 2020. The trademark is classified under Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

RAKUTEN, INC. (52 trademarks)

1-14¬1 TAMAGAWA, SETAGAYA-KU
TOKYO 158-0094 , JP

Entity Type: 03

Rakuten Group, Inc. (63 trademarks)

1-14-1 Tamagawa,

Entity Type: 03

Trademark Details

Filing Date

November 11, 2020

Registration Date

December 2, 2025

First Use Anywhere

January 10, 2023

First Use in Commerce

January 10, 2023

Published for Opposition

June 15, 2021

Goods & Services

Educational services, providing training in the field of medicines, medical devices, pharmaceuticals, clinical trials and health care; Teaching and training services, namely, courses, classes, lessons and seminars in the field of medicines, pharmaceuticals and health care; Arranging, conducting and organization of congresses, conferences, conventions and symposiums in the field of medicines, pharmaceuticals and health care; Educational services, namely, providing classes, seminars, and lectures, all in the field of the diagnosis and treatment of cancer; education in the nature of classes, seminars, and training in the oncology field

Compilation of statistical data relating to medical research for business purposes

Testing and research on medical treatment methods and techniques; Provision of medical and scientific research information on clinical trials; Research and development in the field of immunology; Testing and research on pharmaceuticals; Medical and pharmacological research services and clinical trials for others; Research, development, and consultation related thereto in the field of medicine; Providing medical and scientific research information in the field of pharmaceuticals; Pharmaceutical drug development services; Medical laboratories; Design and development of medical technology; Scientific, biological and medical research; Conducting clinical trials for others

Medical services; Medical information; Providing medical information from a web site; Medical testing for diagnostic or treatment purposes; Medical treatment services; Medical care services; Medical analysis services relating to the treatment of persons provided by a medical laboratory; Medical services in the field of oncology; Medical consultation; Medical advisory services; Compilation of medical reports, namely, medical reporting services; Issuing of medical reports, namely, medical reporting services; Medical and healthcare clinics; Medical assistance; Healthcare services; Rental of medical machines and apparatus; Consultancy and information services relating to the diagnostic, prophylactic, and therapeutic properties of medical products; Providing information in the field of health care, medical conditions, medicine and pharmaceuticals; Providing medical information on pharmaceuticals and oncology platforms; Providing medical and patient support information in relation to the treatment of cancer; Counselling services, namely, medical counselling for patients diagnosed with cancer; Information services in the field of diagnosing and treating cancer; Providing online information services, namely, prescription drug information regarding diagnostic, prophylactic, and therapeutic properties; Providing information in the field of medicine; Providing medical information regarding medical conditions and diseases and providing information relating to the health effects of pharmaceuticals; Providing information and content about cancer, cancer recovery, cancer treatment, and post-cancer treatment care and survival via a website; Providing information about cancer, cancer recovery, cancer treatment, and post-cancer treatment care and survival via an online searchable database; Medical diagnostic testing and reporting services; Genetic testing for diagnostic and treatment purposes; Providing healthcare information regarding cancer drugs and cancer treatment; Maintaining personal medical history records and files

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 2, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 2, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 12, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Nov 12, 2025 CNPR
DIVISIONAL PROCESSING COMPLETE
Oct 27, 2025 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 23, 2025 AITU
EXAMINER'S AMENDMENT ENTERED
Aug 28, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 28, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 28, 2025 GNEA
SU-EXAMINER'S AMENDMENT WRITTEN
Aug 28, 2025 SNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 14, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 14, 2025 GNRT
SU - NON-FINAL ACTION - WRITTEN
May 14, 2025 CNRT
ASSIGNED TO LIE
Dec 14, 2024 ALIE
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 13, 2024 CRFA
DIVISIONAL REQUEST RECEIVED
Nov 14, 2024 DRRR
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 14, 2024 TROA
TEAS REQUEST TO DIVIDE RECEIVED
Nov 14, 2024 ERTD
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 9, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 9, 2024 GNRT
SU - NON-FINAL ACTION - WRITTEN
Sep 9, 2024 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Aug 7, 2024 SUPC
USE AMENDMENT FILED
Aug 5, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Aug 5, 2024 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 22, 2024 EXRA
SOU EXTENSION 5 GRANTED
Feb 21, 2024 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 21, 2024 AITU
SOU EXTENSION 5 FILED
Feb 5, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Feb 5, 2024 EEXT
ASSIGNED TO EXAMINER
Oct 26, 2023 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 10, 2023 EXRA
SOU EXTENSION 4 GRANTED
Aug 8, 2023 EX4G
SOU EXTENSION 4 FILED
Aug 8, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 8, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 25, 2023 EXRA
SOU EXTENSION 3 GRANTED
Jan 23, 2023 EX3G
SOU EXTENSION 3 FILED
Jan 23, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 23, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2022 EXRA
SOU EXTENSION 2 GRANTED
Aug 5, 2022 EX2G
SOU EXTENSION 2 FILED
Aug 5, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 5, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 22, 2022 EXRA
SOU EXTENSION 1 GRANTED
Jan 20, 2022 EX1G
SOU EXTENSION 1 FILED
Jan 20, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 20, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 10, 2021 NOAM
POST PUBLICATION AMENDMENT - ENTERED
Jul 20, 2021 CHPB
ASSIGNED TO PETITION STAFF
Jul 19, 2021 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jun 24, 2021 EPPA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 15, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jun 15, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 26, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 10, 2021 CNSA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 5, 2021 ASGN
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 23, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 23, 2021 GNSL
SUSPENSION LETTER WRITTEN
Apr 23, 2021 CNSL
EXAMINER'S AMENDMENT ENTERED
Apr 23, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 23, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 23, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 23, 2021 CNEA
ASSIGNED TO EXAMINER
Apr 14, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 11, 2021 NWOS
NEW APPLICATION ENTERED
Nov 14, 2020 NWAP